Acute lymphocytic leukemia

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
月曜日, 6月 14, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Clinical medicine, Medicine, Acute lymphocytic leukemia, Leukemia, Gene therapy, Acute lymphoblastic leukemia, Chimeric antigen receptor T cell, Lymphoblast, T-cell acute lymphoblastic leukemia, Acute leukemia

The "CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape.
  • CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Therapeutic Assessment
    This segment of the report provides insights about the different CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Diet and Exercise May Increase Efficacy of Chemotherapy for Children with Cancer

Retrieved on: 
木曜日, 4月 1, 2021
Cancer, Clinical medicine, Medicine, Cancer treatments, Pediatric cancers, Acute lymphocytic leukemia, Antineoplastic drugs, Oncology, Acute lymphoblastic leukemia, Leukemia, Chemotherapy, Minimal residual disease

This intervention, which improved chemotherapy outcomes for children being treated at two institutions, will be further studied through a national trial later this year.

Key Points: 
  • This intervention, which improved chemotherapy outcomes for children being treated at two institutions, will be further studied through a national trial later this year.
  • B-cell acute lymphoblastic leukemia (B-ALL), a cancer affecting the white blood cells in the bone marrow, is the most common type of cancer in children.
  • Notably, adherence to the diet and exercise program reduced the chances of detecting MRD after chemotherapy in all patients, regardless of their starting body weight or composition.
  • Adherence to the diet portion of the program was high: 82% of the study participants achieved a caloric deficit throughout their time on chemotherapy.

Global Acute Lymphoblastic Leukemia Treatment Market Research Report (2020 to 2025) - by Types of Cell, Therapy and Region

Retrieved on: 
水曜日, 3月 24, 2021
Cancer, Clinical medicine, Medicine, Acute lymphocytic leukemia, Pediatric cancers, Antineoplastic drugs, Leukemia, Acute lymphoblastic leukemia, Chemotherapy, Book:Cancer, Biphenotypic acute leukaemia

Based on Therapy, the Acute Lymphoblastic Leukemia Treatment Market is examined across Chemotherapy, Radiation Therapy, Stem Cell Transplantation, and Targeted Therapy.

Key Points: 
  • Based on Therapy, the Acute Lymphoblastic Leukemia Treatment Market is examined across Chemotherapy, Radiation Therapy, Stem Cell Transplantation, and Targeted Therapy.
  • Based on Geography, the Acute Lymphoblastic Leukemia Treatment Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • What are the technology trends and regulatory frameworks in the Global Acute Lymphoblastic Leukemia Treatment Market?
  • What are the modes and strategic moves considered suitable for entering the Global Acute Lymphoblastic Leukemia Treatment Market?

Insights on the Acute Lymphoblastic Leukemia Treatment Global Market to 2025 - Cumulative Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
月曜日, 3月 22, 2021
Health, Oncology, Pediatric cancers, Acute lymphocytic leukemia, Leukemia, Acute lymphoblastic leukemia, Medical specialties, Clinical medicine, Lymphomatous acute lymphoblastic leukemia

What is the market size and forecast of the Global Acute Lymphoblastic Leukemia Treatment Market?

Key Points: 
  • What is the market size and forecast of the Global Acute Lymphoblastic Leukemia Treatment Market?
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Acute Lymphoblastic Leukemia Treatment Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Acute Lymphoblastic Leukemia Treatment Market?
  • What are the modes and strategic moves considered suitable for entering the Global Acute Lymphoblastic Leukemia Treatment Market?

BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Retrieved on: 
火曜日, 12月 8, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medical specialties, Cancer, Breakthrough therapy, Acute lymphocytic leukemia, Leukemia, Blinatumomab, Immunology, Pediatric cancers, Lymphoid leukemia, Acute lymphoblastic leukemia, Tisagenlecleucel, Acute Lymphoblastic Leukemia (ALL), BLINCYTO® (blinatumomab), BeiGene

This approval of BLINCYTO provides us with an opportunity to offer adult patients in China with relapsed or refractory B-cell precursor ALL the first approved immunotherapy treatment for their disease.

Key Points: 
  • This approval of BLINCYTO provides us with an opportunity to offer adult patients in China with relapsed or refractory B-cell precursor ALL the first approved immunotherapy treatment for their disease.
  • Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a rapidly progressing cancer of the blood and bone marrow that occurs in both adults and children1.
  • ALL accounts for approximately 20% of all adult leukemia, and in China there were an estimated 82,607 new cases of leukemia in 20182,3.
  • In China, BLINCYTO is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.

Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting

Retrieved on: 
水曜日, 11月 4, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cancer, Medical specialties, Clinical medicine, Pediatric cancers, Acute myeloid leukemia, Acute lymphocytic leukemia, Leukemia, 7+3, Acute lymphoblastic leukemia, Oncological emergencies, Leukostasis, Childhood leukemia, Vibecotamab, Xencor, Inc.

"Data from the Phase 1 study of vibecotamab suggest that patients with AML having low baseline disease burden and specific T-cell signatures may be more likely to respond to treatment with vibecotamab.

Key Points: 
  • "Data from the Phase 1 study of vibecotamab suggest that patients with AML having low baseline disease burden and specific T-cell signatures may be more likely to respond to treatment with vibecotamab.
  • At data cut off for submitting the abstract, 104 patients with AML, one patient with B cell acute lymphoblastic leukemia and one patient with chronic myeloid leukemia had received vibecotamab.
  • Patients received doses of vibecotamab ranging from 0.003 mcg/kg to 12 mcg/kg.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Firearm Manufacturer's Donation Raises Over $47,000 For 3-Year-Old Battling Leukemia

Retrieved on: 
月曜日, 10月 26, 2020
Pediatric cancers, Acute lymphocytic leukemia, Childhood leukemia, Leukemia, Branches of biology, Acute lymphoblastic leukemia, Lymphoblast, Medical specialties, Clinical medicine

Preslie was diagnosed with B-cell acute lymphoblastic leukemia (ALL) in April of this year and still has two years of treatment left.

Key Points: 
  • Preslie was diagnosed with B-cell acute lymphoblastic leukemia (ALL) in April of this year and still has two years of treatment left.
  • All proceeds from the sales and auctions of the rifles are being presented to the Mantsch family to assist with the medical expenses associated with childhood leukemia.
  • The rifles, which sold for $620 each, sold out within a matter of hours after Henry's initial announcement.
  • The first and last serial numbers in the series were put up for auction and pulled in an additional $6,525 and $2,075, respectively.

Acute Lymphocytic Leukemia Market to 2030 - Insight, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
月曜日, 9月 14, 2020
Pharmaceutical, Health, Oncology, Cancer, RTT, Acute lymphocytic leukemia, Medical specialties, Pediatric cancers, Leukemia, Lymphoid leukemia, Acute lymphoblastic leukemia, Lymphoblast, Childhood leukemia, Precursor B-cell lymphoblastic leukemia

The "Acute Lymphocytic Leukemia (ALL): Market Insight, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Lymphocytic Leukemia (ALL): Market Insight, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • It progresses more slowly than acute leukemia and may not require treatment for a long time after it is diagnosed.
  • Acute lymphocytic leukemia (ALL), also known as acute lymphoblastic leukemia, is a type of cancer that affects the blood and bone marrow.
  • To understand the future market competition in the ALL market and Insightful review of the key market drivers and barriers.

Acute Lymphoblastic Leukemia Market is Expected to Grow with 4.8% CAGR During the Study Period of 2017-30 in 7 Major Markets

Retrieved on: 
木曜日, 6月 25, 2020
RTT, Acute lymphocytic leukemia, Cancer, Leukemia, Lymphoblast, Acute lymphoblastic leukemia, Branches of biology, Acute leukemia, B-cell leukemia

CAR-T cell therapies are expected to dominate the Acute lymphoblastic leukemia market as five of the immunotherapies in the pipeline are geared up to enter the market by 2023."

Key Points: 
  • CAR-T cell therapies are expected to dominate the Acute lymphoblastic leukemia market as five of the immunotherapies in the pipeline are geared up to enter the market by 2023."
  • LAS VEGAS, June 25, 2020 /PRNewswire/ -- DelveInsight has announced the expansion of the forecast period to 2020-2030 for its report on ' Acute Lymphoblastic Leukemia (ALL) Market Insight, Epidemiology and Market Forecast -2030' .
  • B-cell lymphoblastic leukemia accounted for the majority of cases, i.e., 82% of total ALL cases, in comparison of T-cell lymphoblastic leukemia.
  • The United States accounted for the highest Acute lymphoblastic leukemia market size, followed by Germany and France among the 7MM countries.

Acute Lymphoblastic Leukemia Market is Expected to Grow with 4.8% CAGR During the Study Period of 2017-30 in 7 Major Markets

Retrieved on: 
木曜日, 6月 25, 2020
RTT, Acute lymphocytic leukemia, Cancer, Leukemia, Lymphoblast, Acute lymphoblastic leukemia, Branches of biology, Acute leukemia, B-cell leukemia

CAR-T cell therapies are expected to dominate the Acute lymphoblastic leukemia market as five of the immunotherapies in the pipeline are geared up to enter the market by 2023."

Key Points: 
  • CAR-T cell therapies are expected to dominate the Acute lymphoblastic leukemia market as five of the immunotherapies in the pipeline are geared up to enter the market by 2023."
  • LAS VEGAS, June 25, 2020 /PRNewswire/ -- DelveInsight has announced the expansion of the forecast period to 2020-2030 for its report on ' Acute Lymphoblastic Leukemia (ALL) Market Insight, Epidemiology and Market Forecast -2030' .
  • B-cell lymphoblastic leukemia accounted for the majority of cases, i.e., 82% of total ALL cases, in comparison of T-cell lymphoblastic leukemia.
  • The United States accounted for the highest Acute lymphoblastic leukemia market size, followed by Germany and France among the 7MM countries.